Fcab

F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies

Retrieved on: 
Wednesday, July 5, 2023
Antibody, Cancer, Partnership, Therapy, Research, Patient, Fcab, Immune system, Vaccine, Takeda

LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics , an invoX company (“F-star”), today announced that it has entered into a strategic discovery collaboration and licence agreement with Takeda.

Key Points: 
  • LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics , an invoX company (“F-star”), today announced that it has entered into a strategic discovery collaboration and licence agreement with Takeda.
  • Under the terms of the agreement, F-star and Takeda will jointly research and develop novel Fcab domains against undisclosed immuno-oncology targets.
  • Takeda will receive a worldwide, exclusive royalty-bearing licence to research, develop, and commercialise antibodies incorporating Fcab domains arising from the collaboration, and F-star will retain the right to research, develop, and commercialise antibodies incorporating certain other Fcab domains.
  • Takeda continues to develop such licensed antibodies outside the scope of the partnership announced today.

F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody

Retrieved on: 
Wednesday, July 20, 2022
Time, Nasdaq, Beauville–Laszlo theorem, Maintenance, Forward-looking statement, SEC, Research, IO, Drug discovery, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, Fcab, Â, Patent, CNS, Therapy, Safety, NASDAQ, Cancer, Takeda, CD137, Immunotherapy, Drug development, Technology, Company, Patient, PSLRA, Annual report, Terminology, Communication, Pharmaceutical industry

Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-stars proprietary Fcab and mAb2 platforms.

Key Points: 
  • Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-stars proprietary Fcab and mAb2 platforms.
  • Takeda will be responsible for all research, development, and commercialization activities under the agreement.
  • We believe there is enormous potential for our mAb2 platform to produce multiple next-generation bispecific antibody therapeutics beyond our current proprietary pipeline and this agreement with Takeda represents F-stars long-term commitment to realising this potential through partnerships.
  • Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication.

Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Antibodies, Branches of biology, Medicine, Immunology, Glycoproteins, Bispecific monoclonal antibody, Synthetic antibody, Fragment antigen-binding, Immune system, Fcab, Recombinant antibodies

LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.

Key Points: 
  • LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.
  • The ALLIGATOR-FAB library is built on multiple antibody backbones with optimal drug development properties to further increase the structural diversity of generated antibodies.
  • The ALLIGATOR-FAB library has been shown to generate pools of highly diverse and functional antibody variants.
  • With the two human antibody libraries at hand, Alligator has the capacity to generate therapeutic mono- and bispecific antibodies against virtually any target", said Per Norln, CEO of Alligator Bioscience.

Alligator Bioscience launches ALLIGATOR-FAB™ - a novel human antibody library

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Antibodies, Branches of biology, Medicine, Immunology, Glycoproteins, Bispecific monoclonal antibody, Synthetic antibody, Fragment antigen-binding, Immune system, Fcab, Recombinant antibodies

LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.

Key Points: 
  • LUND, Sweden, Dec. 10, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX)today announced the completion of a novel proprietary human synthetic antibody library in Fab (Fragment antigen-binding) format - ALLIGATOR-FAB.
  • The ALLIGATOR-FAB library is built on multiple antibody backbones with optimal drug development properties to further increase the structural diversity of generated antibodies.
  • The ALLIGATOR-FAB library has been shown to generate pools of highly diverse and functional antibody variants.
  • With the two human antibody libraries at hand, Alligator has the capacity to generate therapeutic mono- and bispecific antibodies against virtually any target", said Per Norln, CEO of Alligator Bioscience.

AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners

Retrieved on: 
Thursday, August 20, 2020
Biotechnology, Pharmaceutical, Health, Medical specialties, Clinical medicine, Branches of biology, Immunology, Glycoproteins, Antibodies, Immune system, Bispecific monoclonal antibody, Monoclonal antibodies, Immunoglobulin G, Fcab

OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences.

Key Points: 
  • OrthoMab is a clinically validated platform that uses the most advanced computational and experimental protein engineering methods to create IgG-like bispecific antibodies from any two antibody sequences.
  • Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs.
  • Dr. Tim Jacobs, who led multiple bispecific antibody programs as CTO of Dualogics, joined AbCelleras team in early August.
  • I am extremely excited to be joining the AbCellera team and look forward to bringing best-in-class bispecific and protein-engineering capabilities to our partners.

F-star Therapeutics to Participate in BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, August 5, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Medical specialties, Life sciences, Clinical medicine, Immunology, Biotechnology, F-star, Monoclonal antibody, Bispecific monoclonal antibody, Antibody, Biopharmaceutical, Fcab

F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announces that Eliot Forster, Chief Executive Officer, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on Monday August 10, 2020.

Key Points: 
  • F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announces that Eliot Forster, Chief Executive Officer, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on Monday August 10, 2020.
  • The Company will also be available for one to one meetings during the conference, on Monday August 10 and Tuesday August 11.
  • F-star is a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy.
  • Through its proprietary tetravalent, bispecific antibody (mAb) format, F-stars mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020

Retrieved on: 
Tuesday, June 16, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Monoclonal antibodies, Glycoproteins, Antibodies, Immune system, Bispecific monoclonal antibody, Cancer immunotherapy, Immunoglobulin G, Fcab

SAN DIEGO, June 16, 2020 /PRNewswire/ --Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure.

Key Points: 
  • SAN DIEGO, June 16, 2020 /PRNewswire/ --Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure.
  • The technology was presented at the BIO Digital 2020.
  • "The beauty of the PACbodyTM bispecific antibody platform is that it's a 'plug and play' technology to quickly make an IgG-like bispecific antibody the native structure of both arms of the bispecific antibody is maintained," said Dr. Hui Zou, PhD, Chief Scientific Officer (CSO) of Phanes Therapeutics.
  • In addition, we'd like to leverage our PACbodyTM technology to help advance the innovation of other players in the industry."

Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

Retrieved on: 
Tuesday, February 18, 2020
Medical specialties, Medicine, Immunology, Monoclonal antibodies, Bispecific monoclonal antibody, Antibody, Monoclonal antibody therapy, Fcab

Bispecific antibodies are a novel class of antibody therapeutics that act by simultaneously binding two separate and unique antigens (or different epitopes of the same antigen).

Key Points: 
  • Bispecific antibodies are a novel class of antibody therapeutics that act by simultaneously binding two separate and unique antigens (or different epitopes of the same antigen).
  • The Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade.
  • Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics.
  • One of the key objectives of the report was to estimate the existing market size and the future opportunity for bispecific antibody therapeutics, for the next decade.

Bispecific Antibodies for Cancer: Worldwide Market Analysis & Outlook Report, 2019 to 2023 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 13, 2019
Health, Oncology, Pharmaceutical, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, Bispecific monoclonal antibody, Antibody, Fcab, Trifunctional antibody

The bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

Key Points: 
  • The bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.
  • The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period.
  • Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy.
  • Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years.

The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022.

Retrieved on: 
Thursday, November 1, 2018
Medicine, Immunology, Clinical medicine, Monoclonal antibodies, Immune system, Antineoplastic drugs, Biotechnology, Antibody, Bispecific monoclonal antibody, Fcab

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies

Key Points: 
  • NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies
    The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023.
  • In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.
  • The 217-page report provides clear detailed insight into the next-generation antibody therapies market.
  • Forecast of the Global Next-Generation Antibody Therapies market by Submarket: